
Ashkan Shoamanesh, MD, discusses individualizing stroke prevention after ENRICH-AF, from LAAO to factor XI inhibitors to the ASPIRE trial.

Ashkan Shoamanesh, MD, is an associate professor of medicine and the Marta and Owen Boris Chair in Stroke Research and Care at McMaster University.

Ashkan Shoamanesh, MD, discusses individualizing stroke prevention after ENRICH-AF, from LAAO to factor XI inhibitors to the ASPIRE trial.

Ashkan Shoamanesh, MD, explains ENRICH-AF's mixed stroke and bleeding results, and a dosing signal that may point to a safer approach.

Ashkan Shoamanesh, MD, discusses a series of abstracts presented at ESOC 2026 reinforcing asundexian’s protective effect in patients at risk of ischemic stroke or TIA.

Shoamanesh discusses the positive data from OCEANIC-STROKE, a phase 3 trial comparing the investigative FXIa inhibitor to placebo in patients with prior ischemic stroke.